← FDA DRUG APPROVALS

FDA ANDA · ANDA091541

LOSARTAN POTASSIUM

Sponsor: MICRO LABS

APPLICATION
ANDA091541
TYPE
ANDA
ORIGINAL APPROVAL
2012-09-24
LATEST ACTION
2026-04-10
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LOSARTAN POTASSIUMPrescription
LOSARTAN POTASSIUM 50MG · TABLET · ORAL
LOSARTAN POTASSIUMPrescription
LOSARTAN POTASSIUM 100MG · TABLET · ORAL
LOSARTAN POTASSIUMPrescription
LOSARTAN POTASSIUM 25MG · TABLET · ORAL

Approval history

2026-04-10Labeling · Supplement 15 · standardAP
2023-08-23Labeling · Supplement 13 · standardAP
2019-05-07Labeling · Supplement 12 · standardAP
2016-06-09Labeling · Supplement 6 · standardAP
2015-10-07Labeling · Supplement 5 · standardAP
2014-11-05Labeling · Supplement 3 · standardAP
2013-06-11Labeling · Supplement 2 · standardAP
2013-01-31Labeling · Supplement 1 · standardAP
2012-09-24OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →